For research use only. Not for therapeutic Use.
Torin 1（Cat No.:I000853）is a potent and selective inhibitor of mTOR (mechanistic target of rapamycin) kinase, targeting both mTORC1 and mTORC2 complexes. Unlike rapamycin, which only partially inhibits mTORC1, Torin 1 provides comprehensive suppression of mTOR signaling, blocking downstream pathways such as Akt, S6K, and 4E-BP1. This inhibition leads to reduced cell growth, proliferation, and protein synthesis while promoting autophagy. Torin 1 is widely used in cancer research, autophagy studies, and investigations into metabolic disorders, providing valuable insights into the role of mTOR signaling in health and disease.
| Catalog Number | I000853 |
| CAS Number | 1222998-36-8 |
| Synonyms | 1-[4-(4-propanoylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-9-quinolin-3-ylbenzo[h][1,6]naphthyridin-2-one |
| Molecular Formula | C₃₅H₂₈F₃N₅O₂ |
| Purity | ≥95% |
| Target | Autophagy |
| Solubility | DMSO: ≤ 6 mg/mL (Need ultrasonic or warming) |
| Storage | 3 years -20C powder |
| IUPAC Name | 1-[4-(4-propanoylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-9-quinolin-3-ylbenzo[h][1,6]naphthyridin-2-one |
| InChI | InChI=1S/C35H28F3N5O2/c1-2-32(44)42-15-13-41(14-16-42)31-11-9-26(19-28(31)35(36,37)38)43-33(45)12-8-24-20-40-30-10-7-22(18-27(30)34(24)43)25-17-23-5-3-4-6-29(23)39-21-25/h3-12,17-21H,2,13-16H2,1H3 |
| InChIKey | AKCRNFFTGXBONI-UHFFFAOYSA-N |
| SMILES | CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F |
| Reference | </br>1:Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes. Xu S, Li L, Li M, Zhang M, Ju M, Chen X, Gu H.Oxid Med Cell Longev. 2017;2017:5930639. doi: 10.1155/2017/5930639. Epub 2017 Mar 16. PMID: 28400912 Free PMC Article</br>2:Mammalian target of rapamycin inhibitors, temsirolimus and torin 1, attenuate stemness-associated properties and expression of mesenchymal markers promoted by phorbol-myristate-acetate and oncostatin-M in glioblastoma cells. Chandrika G, Natesh K, Ranade D, Chugh A, Shastry P.Tumour Biol. 2017 Mar;39(3):1010428317695921. doi: 10.1177/1010428317695921. PMID: 28351321 </br>3:Intra-articular injection of Torin 1 reduces degeneration of articular cartilage in a rabbit osteoarthritis model. Cheng NT, Guo A, Cui YP.Bone Joint Res. 2016 Jun;5(6):218-24. doi: 10.1302/2046-3758.56.BJR-2015-0001. PMID: 27301478 Free PMC Article</br>4:The protective role of autophagy in experimental osteoarthritis, and the therapeutic effects of Torin 1 on osteoarthritis by activating autophagy. Cheng NT, Guo A, Meng H.BMC Musculoskelet Disord. 2016 Apr 6;17:150. doi: 10.1186/s12891-016-0995-x. PMID: 27052304 Free PMC Article</br>5:Torin 1 partially corrects vigabatrin-induced mitochondrial increase in mouse. Vogel KR, Ainslie GR, Jansen EE, Salomons GS, Gibson KM.Ann Clin Transl Neurol. 2015 Jun;2(6):699-706. doi: 10.1002/acn3.200. Epub 2015 Apr 17. PMID: 26125044 Free PMC Article</br>6:Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Francipane MG, Lagasse E.Oncotarget. 2013 Nov;4(11):1948-62. PMID: 24185040 Free PMC Article |
